Literature DB >> 21771892

International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions.

Magnus Bäck1, Sven-Erik Dahlén, Jeffrey M Drazen, Jilly F Evans, Charles N Serhan, Takao Shimizu, Takehiko Yokomizo, G Enrico Rovati.   

Abstract

The seven-transmembrane G protein-coupled receptors activated by leukotrienes are divided into two subclasses based on their ligand specificity for either leukotriene B(4) or the cysteinyl leukotrienes (LTC(4), LTD(4), and LTE(4)). These receptors have been designated BLT and CysLT receptors, respectively, and a subdivision into BLT(1) and BLT(2) receptors and CysLT(1) and CysLT(2) receptors has been established. However, recent findings have also indicated the existence of putative additional leukotriene receptor subtypes. Furthermore, other ligands interact with the leukotriene receptors. Finally, leukotrienes may also activate other receptor classes, such as purinergic receptors. The aim of this review is to provide an update on the pharmacology, expression patterns, and pathophysiological roles of the leukotriene receptors as well as the therapeutic developments in this area of research.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21771892     DOI: 10.1124/pr.110.004184

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  40 in total

Review 1.  The multifaceted functions of neutrophils.

Authors:  Tanya N Mayadas; Xavier Cullere; Clifford A Lowell
Journal:  Annu Rev Pathol       Date:  2013-09-16       Impact factor: 23.472

2.  MFG-E8-derived peptide attenuates adhesion and migration of immune cells to endothelial cells.

Authors:  Yohei Hirano; Weng-Lang Yang; Monowar Aziz; Fangming Zhang; Barbara Sherry; Ping Wang
Journal:  J Leukoc Biol       Date:  2017-01-17       Impact factor: 4.962

3.  Changes of the GPR17 receptor, a new target for neurorepair, in neurons and glial cells in patients with traumatic brain injury.

Authors:  Heike Franke; Chiara Parravicini; Davide Lecca; Elisa R Zanier; Claudia Heine; Kristina Bremicker; Marta Fumagalli; Patrizia Rosa; Luca Longhi; Nino Stocchetti; Maria-Grazia De Simoni; Marco Weber; Maria P Abbracchio
Journal:  Purinergic Signal       Date:  2013-06-26       Impact factor: 3.765

4.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

Review 5.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

Review 6.  Resolvins and protectins in inflammation resolution.

Authors:  Charles N Serhan; Nicos A Petasis
Journal:  Chem Rev       Date:  2011-07-18       Impact factor: 60.622

Review 7.  Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7.

Authors:  Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati
Journal:  Br J Pharmacol       Date:  2014-07-12       Impact factor: 8.739

Review 8.  Antileukotrienes in upper airway inflammatory diseases.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Kagan Ipci; Ethem Şahin
Journal:  Curr Allergy Asthma Rep       Date:  2015-11       Impact factor: 4.806

Review 9.  Leukotriene receptors as potential therapeutic targets.

Authors:  Takehiko Yokomizo; Motonao Nakamura; Takao Shimizu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Elucidation of the molecular mechanism and the efficacy in vivo of a novel 1,4-benzoquinone that inhibits 5-lipoxygenase.

Authors:  A M Schaible; R Filosa; V Temml; V Krauth; M Matteis; A Peduto; F Bruno; S Luderer; F Roviezzo; A Di Mola; M de Rosa; B D'Agostino; C Weinigel; D Barz; A Koeberle; C Pergola; D Schuster; O Werz
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.